The present invention relates to new compounds of formula I wherein: Z is N and X is CH or N； Y is CONR 5 ； P is phenyl or a 5 or 6 membered heteroaromatic ring containing one or more heteroatoms selected from N, O or S； Q is phenyl or a 5 or 6 membered aromatic heterocyclicc ring containing one or more nitrogen atoms； R is C 1-6 alkylNR 10 R 11 or C 1-6 alkylazetidine； R 10 is hydrogen, C 1 - 6 alkyl, C 2-6 alkenyl, C 2 - 6 alkynyl, C 0 - 6 alkylC 3 - 6 cycloalkyl, C 0 - 6 alkylaryl, C 0 - 6 alkylheteroaryl or C 1 - 6 alkylNR 8 R 9 ； R 11 is C 1 - 6 alkylNR 8 R 9 , C 1 - 6 alkylC 3 - 6 cycloalkyl or C 0 - 6 alkylheterocycloalkyl； as a free base or a pharmaceutically acceptable salt, solvate or solvate of salt thereof, a process for their preparation and new intermediates used therein, pharmaceutical formulations containing said therapeutically active compounds and to the use of said active compounds in therapy.
